


We Claim:

1. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate represented by the formula Sp-4:



having XRPD 2 θ -reflections ($\pm 0.2^\circ$) at 6.1 and 12.7.

2. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 1 further having:

XRPD 2 θ -reflections ($\pm 0.2^\circ$) at about: 8.2, 10.4, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.

3. A pharmaceutical composition comprising crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claims 1 or 2 and a pharmaceutically acceptable medium.

4. A pharmaceutical composition according to claim 3, further comprising another antiviral agent.


5. A pharmaceutical composition according to claim 4, wherein the another antiviral agent is a HCV NS3 protease inhibitor.

6. A pharmaceutical composition according to claim 4, wherein the another antiviral agent is a HCV NS5A inhibitor.

7. A pharmaceutical composition according to claim 4, wherein the another antiviral agent is a HCV NS3 protease inhibitor and a HCV NS5A inhibitor.

8. A tablet comprising the crystalline Sp-4 of claims 1 or 2.

9. A tablet comprising Sp-4:



wherein at least 70% of the Sp-4 is the crystalline Sp-4 of claims 1 or 2.

10. The tablet of claim 9, wherein at least 80% of the Sp-4 is the crystalline Sp-4 of claims 1 or 2.

11. The tablet of claim 9, wherein at least 90% of the Sp-4 is the crystalline Sp-4 of claims 1 or 2.

Dated this the 26th day of October, 2012.

Amrish Tiwari
Of K&S Partners
Attorney for the Applicant
IN-PA/1202